Posted in | News | Nanomedicine | Nanobusiness

NanoBio to Present Studies at ICAAC 2009

NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns. The company also announced that data from a large GLP toxicity study in rabbits demonstrated similarly robust immune responses without signs of toxicity or inflammation.

Data from both studies will be presented on Sunday, September 13th at 11:15 am at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at the Moscone Center, San Francisco, CA. The poster references are as follows:

Poster # G1-877: Intranasal W805EC Adjuvanted Fluzone Provides Robust Immunity and Cross-Protection in Ferrets

Poster # G1-878: A GLP Toxicity and Immunogenicity Study of NB-1008, an Intranasal W805EC-Adjuvanted-Fluzone Vaccine

NanoBio will sponsor corporate booth # 1711 at ICAAC, where information on the company’s development programs for its vaccine, dermatological and anti-infective programs will be available.

About NanoBio’s Vaccine Platform

NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcus, anthrax, smallpox and other diseases. The company’s NanoStat™ adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen sparing qualities; cross-protection against strains not included in the vaccine; ability to adjuvant multiple antigen types without inducing inflammation; thermal stability of the vaccine; and removing the need for needles.

NanoBio Corp. announced earlier in 2009 that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered intranasally. This Phase 1 study is ongoing.

NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoBio Corp.. (2019, March 18). NanoBio to Present Studies at ICAAC 2009. AZoNano. Retrieved on May 24, 2022 from https://www.azonano.com/news.aspx?newsID=13540.

  • MLA

    NanoBio Corp.. "NanoBio to Present Studies at ICAAC 2009". AZoNano. 24 May 2022. <https://www.azonano.com/news.aspx?newsID=13540>.

  • Chicago

    NanoBio Corp.. "NanoBio to Present Studies at ICAAC 2009". AZoNano. https://www.azonano.com/news.aspx?newsID=13540. (accessed May 24, 2022).

  • Harvard

    NanoBio Corp.. 2019. NanoBio to Present Studies at ICAAC 2009. AZoNano, viewed 24 May 2022, https://www.azonano.com/news.aspx?newsID=13540.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit